KFREAIN: Design of A Kernel-Level Forensic Layer for Improving Real-Time Evidence Analysis Performance in IoT Networks

An exponential increase in number of attacks in IoT Networks makes it essential to formulate attack-level mitigation strategies. This paper proposes design of a scalable Kernel-level Forensic layer that assists in improving real-time evidence analysis performance to assist in efficient pattern analysis of the collected data samples. It has an inbuilt Temporal Blockchain Cache (TBC), which is refreshed after analysis of every set of evidences. The model uses a multidomain feature extraction engine that combines lightweight Fourier, Wavelet, Convolutional, Gabor, and Cosine feature sets that are selected by a stochastic Bacterial Foraging Optimizer (BFO) for identification of high variance features. The selected features are processed by an ensemble learning (EL) classifier that use low complexity classifiers reducing the energy consumption during analysis by 8.3% when compared with application-level forensic models. The model also showcased 3.5% higher accuracy, 4.9% higher precision, and 4.3% higher recall of attack-event identification when compared with standard forensic techniques. Due to kernel-level integration, the model is also able to reduce the delay needed for forensic analysis on different network types by 9.5%, thus making it useful for real-time & heterogenous network scenarios

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Analysis of Extended Pile Gate Trapezoidal Bulk FinFET

With technology scaling, innovative approaches in the device design are increasingly being explored. Improving device design is one of the focus areas for meeting the demand for low power high-speed circuit design. FinFET being the most promising device structure within the nanoscale regime, different structure variants of FinFET have been proposed and successfully implemented. In this paper, bulk FinFET device design is modified with a new design approach. Two different Si bulk trapezoidal FinFET devices, one with stacked gate and another with extended stacked gate are implemented using the 3D TCAD tool. The improvement in the performance metrics is denoted after comparing it with a simple trapezoidal Bulk FinFET device. Investigated performance metrics include subthreshold slope, Drain-Induced Barrier Lowering, Leakage Current, transconductance generation factor and threshold voltage and internal capacitance across Gate-Substrate, Gate-Drain and Gate -Source terminals of the device

Exploring Low Power Design Through Performance Analysis of FinFET for Fin Shape Variations

With concern of global warming, low power design is an important research domain for scientist and engineers. Focusing upon the energy saving trend, this paper compares the performance analysis of all possible fin shapes in a 16 nm Bulk FinFET device from low power design perspective. Performance metrics include transconductance, transconductance generation factor (TGF), on/off current ratio, Subthreshold swing (SS), Drain Induced Barrier Lowering (DIBL) and power consumption. Low power system design feasibility with the optimized round fin shape resulting from the comparative analysis is justified by implementing N and P FinFET devices with perfectly matched VI characteristics. Prospective usage to meet recent developments in system design and control engineering with power optimization and scalability success in round FinFET device is also reviewed through this work